"All of the approved Alzheimer's disease drugs operate by one of two mechanisms -- cholinesterase inhibition or NMDA-receptor antagonism," noted Bengt Winblad, M.D., Ph.D., Head of the Karolinska Institutet's Alzheimer's Disease Research Center. "The body of preclinical and clinical data generated thus far convinces me that Dimebon is exerting its effects through a different mechanism. The data presented today support the hypothesis that Dimebon improves mitochondrial dysfunction. This is a novel mechanism that may, in part, explain the clinical benefits seen in Alzheimer's patients treated with Dimebon."
About the Pivotal Study
Dimebon's first pivotal Alzheimer's trial was a randomized,
double-blind, placebo-controlled study of 183 patients with mild to
moderate Alzheimer's disease. In this study, patients treated with Dimebon
experienced statistically significant improvements compared to placebo in
all the key aspects of the disease: memory and thinking, activities of
daily living, behavior and overall function -- after both six months and a
full year of treatment. Dimebon's benefit over placebo continued
|SOURCE Medivation, Inc.|
Copyright©2008 PR Newswire.
All rights reserved